Methods of Treating Steroid Resistant Diseases and Conditions

Abstract

Disclosed herein are methods treating and identifying a subject having a steroid resistant disease or condition.

1 .- 18 . (canceled) 
     
     
         19 . A method for identifying and treating a subject having a steroid resistant disease or condition comprising:
 a. obtaining a biological sample from the subject;   b. determining the expression level of CBX7 in the sample;   c. identifying the subject as having a steroid resistant disease or condition if the CBX7 level from the sample is elevated as compared to a control CBX7 level; and   d. administering a compound that decreases CBX7 activity to the identified subject.   
     
     
         20 . The method of claim  18  or  19 , wherein the compound is a CBX7 inhibitor. 
     
     
         21 . The method of  claim 20 , wherein the CBX7 inhibitor is selected from the group consisting of a small-molecule inhibitor, a chemical inhibitor, and antibody, a CBX7 siRNA and combinations thereof. 
     
     
         22 . The method of  claim 20 , wherein the CBX7 inhibitor is MS37452 or UNC3866. 
     
     
         23 . The method of  claim 19 , wherein the steroid resistant disease is an inflammatory disease selected from the group consisting of asthma, an inflammatory lung disease, allergic rhinitis, atopic dermatitis and sinusitis. 
     
     
         24 . The method of  claim 23 , wherein the inflammatory lung disease is associated with a chronic obstructive disease of the airways. 
     
     
         25 . The method of  claim 23 , wherein the inflammatory lung disease is associated with viral induced inflammation. 
     
     
         26 . The method of  claim 23 , wherein the inflammatory lung disease is triggered by the subject's exposure to environmental conditions selected from the group consisting of second-hand smoke, primary tobacco smoke, and an allergen. 
     
     
         27 . The method of  claim 23 , wherein the inflammatory disease is asthma. 
     
     
         28 . The method of  claim 19 , wherein the step of administering is by an administration route selected from the group consisting of injection, oral, inhalation and topical. 
     
     
         29 . The method of  claim 19 , wherein the biological sample is selected from the group consisting of serum, plasma, blood, sputum, peripheral blood mononuclear cells (PBMCs), epithelial cells, sinus tissue, nasal tissue, and lung tissue. 
     
     
         30 .- 72 . (canceled)